How did Lipocine (LPCN) share information about the LPCN 1154 trial update?

Lipocine shared information via a press release, which is furnished as Exhibit 99.1 and incorporated by reference in the report.

Lipocine updates LPCN 1154 postpartum depression trial

Lipocine Inc. filed a current report describing a new press release about the company’s drug candidate LPCN 1154.

Accepted by SEC EDGAR 09/30/2025 - 09:30 AM EDT

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Lipocine Inc. filed a current report describing a new press release about the company’s drug candidate LPCN 1154. The release provides a progress update on the ongoing Phase 3 clinical trial evaluating LPCN 1154 for the treatment of postpartum depression. The report itself does not detail the trial results or timelines but directs readers to the attached press release, which is included as an exhibit and incorporated by reference.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lipocine Inc. (LPCN) report in this 8-K filing?

Lipocine Inc. reported that it issued a press release providing a progress update on the ongoing Phase 3 clinical trial of LPCN 1154 for postpartum depression, and furnished that press release as an exhibit.

What is LPCN 1154 according to Lipocine (LPCN)?

LPCN 1154 is described as a Lipocine drug candidate that is currently in an ongoing Phase 3 clinical trial for the treatment of postpartum depression.

Does this Lipocine (LPCN) filing include Phase 3 trial results?

The document states that a press release was issued providing a progress update on the ongoing Phase 3 trial of LPCN 1154; specific trial results or data are not detailed in the text provided.

What exhibit is attached to this Lipocine (LPCN) 8-K?

The filing lists Exhibit 99.1 as a press release providing a progress update on the LPCN 1154 Phase 3 clinical trial in postpartum depression, and Exhibit 104 as the cover page interactive data file.

Who signed this Lipocine (LPCN) 8-K report?

The report was signed on behalf of Lipocine Inc. by Mahesh V. Patel, President and Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

September 30, 2025

LIPOCINE INC.

(Exact name of registrant as specified in its charter)

Commission File No. 001-36357

Delaware

99-0370688

(State or other jurisdiction

of incorporation)

(IRS Employer

Identification Number)

675 Arapeen Drive, Suite 202

Salt Lake City, Utah 84108

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (801) 994-7383

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13©(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		LPCN		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01

Other Events

The Company issued a press release providing a progress update on LPCN 1154’s ongoing Phase 3 clinical trial for Postpartum Depression (PPD). The press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits

The following exhibits are filed with this report:

Exhibit No.		Description
99.1		Press Release Providing Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		LIPOCINE INC.

Date:	September 30, 2025	By:	/s/ Mahesh V. Patel
			Mahesh V. Patel
			President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR